Exagen/$XGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Exagen
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
- Ticker
- $XGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 218
- Headquarters
- Vista, United States
- Website
- www.exagen.com
Exagen Metrics
BasicAdvanced
$191M
-
-$0.80
2.10
-
Price and volume
Market cap
$191M
Beta
2.1
52-week high
$12.23
52-week low
$2.59
Average daily volume
351K
Financial strength
Current ratio
3.185
Quick ratio
2.749
Long term debt to equity
2.052
Total debt to equity
2.264
Interest coverage (TTM)
-2.58%
Profitability
EBITDA (TTM)
-10.772
Gross margin (TTM)
58.64%
Net profit margin (TTM)
-26.61%
Operating margin (TTM)
-18.58%
Effective tax rate (TTM)
-0.26%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-14.92%
Return on equity (TTM)
-113.82%
Valuation
Price to revenue (TTM)
2.487
Price to book
15.61
Price to tangible book (TTM)
15.61
Price to free cash flow (TTM)
-23.313
Free cash flow yield (TTM)
-4.29%
Free cash flow per share (TTM)
-0.321
Growth
Revenue change (TTM)
20.83%
Earnings per share change (TTM)
-10.05%
3-year revenue growth (CAGR)
10.35%
3-year earnings per share growth (CAGR)
-26.61%
What the Analysts think about Exagen
Analyst ratings (Buy, Hold, Sell) for Exagen stock.
Analyst projections of the future price of Exagen stock.
Exagen Financial Performance
Revenues and expenses
Exagen Earnings Performance
Company profitability
Upcoming events
No upcoming events
Exagen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.